Exhibit 99.1
| St. Jude Medical, Inc. Global Headquarters One St. Jude Medical Drive St. Paul, MN 55117-9913 USA Tel 651 756 2000 sjm.com |
News Release
MEDIA CONTACT: | INVESTOR CONTACT: |
Kate Stoltenberg | J.C. Weigelt |
kstoltenberg@sjm.com | jweigelt@sjm.com |
Tel 651 756 3388 | Tel 651 756 4347 |
St. Jude Medical Reports Second Quarter 2015 Results
ST. PAUL, Minn. – July 22, 2015 – St. Jude Medical, Inc. (NYSE: STJ) today reported sales and net earnings for its second quarter ended July 4, 2015.
Second quarter 2015 highlights:
· Net sales increased by approximately 6 percent on a constant currency basis compared to the prior year quarter
· CardioMEMS™ HF System sales totaled approximately $20 million
· Atrial fibrillation revenue increased by approximately 18 percent on a constant currency basis due to global market share gains driven by the St. Jude Medical FlexAbilityTM and TactiCathTM Quartz Contact Force ablation catheters
· Worldwide neuromodulation revenue increased by approximately 17 percent on a constant currency basis, marking the fourth consecutive quarter of sales acceleration on a year over year basis
Second Quarter 2015 Sales
The company reported net sales of $1.410 billion in the second quarter of 2015, a 3 percent decrease compared to net sales of $1.448 billion in the second quarter of 2014. On a constant currency basis, net sales increased by approximately 6 percent compared to the second quarter of 2014.
Commenting on the company’s financial results, St. Jude Medical Chairman, President and Chief Executive Officer Daniel J. Starks said, “St. Jude Medical’s second quarter results reflect the continued success of our innovation-based growth strategy. We remain confident in our key programs that accelerated sales growth in the first half of 2015 and are raising our sales guidance in order to demonstrate our strong outlook for the remainder of the year.”
Cardiac Rhythm Management (CRM)
Total CRM sales, which include implantable cardioverter defibrillator (ICD) and pacemaker products, were $670 million for the second quarter of 2015, a 9 percent decline compared to the prior year quarter. After adjusting for the impact of foreign currency, CRM sales decreased 1 percent compared to the prior year quarter.
Of that total, ICD product sales were $421 million in the second quarter, a 9 percent decline on a reported basis and decreased 2 percent on a constant currency basis compared to the prior year quarter.
Second quarter pacemaker sales were $249 million, an 8 percent decline compared to the prior year quarter. On a constant currency basis, pacemaker product sales increased 1 percent compared to the prior year quarter.
Atrial Fibrillation (AF)
AF product sales for the second quarter totaled $279 million, a 9 percent increase compared to the prior year quarter. On a constant currency basis, AF product sales increased 18 percent compared to the prior year quarter.
Cardiovascular
Total cardiovascular sales, which primarily include structural heart and vascular products, were $343 million for the second quarter of 2015, a 2 percent decline compared to the prior year quarter. On a constant currency basis, cardiovascular sales increased 7 percent compared to the prior year quarter.
Structural heart product sales for the second quarter of 2015 were $159 million, up 2 percent on a constant currency basis compared to the prior year quarter.
Sales of vascular products in the second quarter of 2015 were $184 million, a 12 percent increase on a constant currency basis compared to the prior year quarter.
Neuromodulation
St. Jude Medical sales of neuromodulation products were $118 million in the second quarter of 2015, a 10 percent increase on a reported basis and a 17 percent increase on a constant currency basis compared to the prior year quarter.
Second Quarter Earnings Results
In the second quarter the Company recognized net after-tax benefits of $20 million, or $0.07 per diluted share, primarily related to acquisition-related adjustments, discrete income tax benefits and ongoing restructuring activities. Including these items, reported net earnings for the second quarter of 2015 were $290 million or $1.02 per share, compared with reported net earnings for the second quarter of 2014 of $270 million or $0.93 per share. Reported results also include the $17 million after-tax impact, or $0.06 per diluted share, of amortization of intangible assets.
In accordance with GAAP, reported net earnings for the second quarter 2015 do not include any benefit from the federal research and development tax credit, which has yet to be extended for 2015. Including the benefit of this adjustment and excluding the second quarter net credits and intangible amortization expense, adjusted net earnings for the second quarter of 2015 were $293 million, or $1.03 per share. A reconciliation of the Company’s non-GAAP adjusted results to the Company’s GAAP reported results is provided in the schedules at the end of the press release.
Third Quarter and Full-Year 2015 Sales and Earnings Guidance
For the third quarter, St. Jude Medical expects revenue to grow in the range of 5 percent to 7 percent on a constant currency basis compared to the third quarter of 2014 with currency negatively impacting third quarter revenue by approximately $105 million to $115 million. For the full-year 2015, the company now expects total revenue to grow in the range of 4 percent to 6 percent on a constant currency basis with
currency negatively impacting full-year 2015 revenue by approximately $385 million to $410 million. During its earnings conference call today, St. Jude Medical will provide an update to its range for revenue expectations for the full-year 2015 by product category.
The company expects its consolidated adjusted net earnings for the third quarter of 2015 to be in the range of $0.96 to $0.98 per share and for full-year 2015 consolidated adjusted net earnings to be in the range of $3.96 to $4.00. A further reconciliation of the company’s quarterly and annual guidance is provided in the schedules at the end of the press release.
Conference Call / Webcast
St. Jude Medical’s second quarter earnings call can be heard live via webcast today beginning at 7 a.m. CT via the St. Jude Medical Investor Relations website (investors.sjm.com). Approximately one hour following the call (and archived for 90 days), a replay will be available on the Investor Events and Presentations webpage in the Investor Relations section of the St. Jude Medical website.
St. Jude Medical will also be tweeting live during the call on our Investor Relations Twitter account, @StJudeMedicalIR.
About St. Jude Medical
St. Jude Medical is a global medical device manufacturer dedicated to transforming the treatment of some of the world’s most expensive epidemic diseases. The company does this by developing cost-effective medical technologies that save and improve lives of patients around the world. Headquartered in St. Paul, Minn., St. Jude Medical has four major clinical focus areas that include cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com or follow us on Twitter @StJudeMedicalIR.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended January 3, 2015 and Quarterly Report on Form 10-Q for the fiscal quarter ended April 4, 2015. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.
Summary of 2Q15 Sales and Reconciliation to Constant Currency Sales Growth
(in millions)
(unaudited) | 2Q15 Sales | 2Q14 Sales | Reported %
Change vs.
2Q14 | Constant
Currency %
Change vs.
2Q14 | Reported
$ Change
vs. 2Q14 | Constant
Currency
$ Change
vs. 2Q14 | Foreign
Currency
Impact |
Total Sales | $1,410 | $1,448 | -3% | 6% | -$38 | $80 | -$118 |
Total International Sales | $697 | $779 | -10% | 5% | | | |
Total U.S. Sales | $713 | $669 | 7% | | | | |
Worldwide Cardiac Rhythm Management | $670 | $733 | -9% | -1% | -$63 | -$10 | -$53 |
International Cardiac Rhythm Management | $300 | $351 | -14% | 1% | | | |
U.S. Cardiac Rhythm Management | $370 | $382 | -3% | | | | |
Worldwide ICD | $421 | $462 | -9% | -2% | -$41 | -$11 | -$30 |
International ICD | $156 | $187 | -17% | -1% | | | |
U.S. ICD | $265 | $275 | -4% | | | | |
Worldwide Pacemakers | $249 | $271 | -8% | 1% | -$22 | $1 | -$23 |
International Pacemakers | $144 | $164 | -12% | 2% | | | |
U.S. Pacemakers | $105 | $107 | -2% | | | | |
Worldwide Atrial Fibrillation | $279 | $257 | 9% | 18% | $22 | $47 | -$25 |
International Atrial Fibrillation | $159 | $159 | 0% | 15% | | | |
U.S. Atrial Fibrillation | $120 | $98 | 22% | | | | |
Worldwide Cardiovascular | $343 | $351 | -2% | 7% | -$8 | $25 | -$33 |
International Cardiovascular | $202 | $233 | -13% | 1% | | | |
U.S. Cardiovascular | $141 | $118 | 19% | | | | |
Worldwide Structural Heart | $159 | $171 | -7% | 2% | -$12 | $4 | -$16 |
International Structural Heart | $102 | $116 | -12% | 1% | | | |
U.S. Structural Heart | $57 | $55 | 4% | | | | |
Worldwide Vascular | $184 | $180 | 2% | 12% | $4 | $21 | -$17 |
International Vascular | $100 | $117 | -15% | 0% | | | |
U.S. Vascular | $84 | $63 | 32% | | | | |
Worldwide Neuromodulation | $118 | $107 | 10% | 17% | $11 | $18 | -$7 |
International Neuromodulation | $36 | $36 | 1% | 21% | | | |
U.S. Neuromodulation | $82 | $71 | 15% | | | | |
Note: Percentage changes are based on actual, non-rounded amounts and may not recalculate precisely.
St. Jude Medical, Inc.
Condensed Consolidated Balance Sheets
(in millions)
(Unaudited)
| | July 4, 2015 | | January 3, 2015 | |
Cash and cash equivalents | | $910 | | $1,442 | |
Accounts receivable, net | | 1,240 | | 1,215 | |
Inventories | | 817 | | 784 | |
Other current assets | | 459 | | 473 | |
Property, plant & equipment, net | | 1,298 | | 1,343 | |
Goodwill | | 3,520 | | 3,532 | |
Other intangible assets, net | | 801 | | 851 | |
Other assets | | 589 | | 567 | |
Total assets | | $9,634 | | $10,207 | |
| | | | | |
Current debt obligations | | $1,979 | | $1,593 | |
Other current liabilities | | 1,035 | | 1,073 | |
Long-term debt | | 1,762 | | 2,273 | |
Long-term other liabilities | | 1,017 | | 1,024 | |
Total equity | | 3,841 | | 4,244 | |
Total liabilities & equity | | $9,634 | | $10,207 | |
St. Jude Medical, Inc.
Condensed Consolidated Statements of Earnings
(in millions, except per share amounts)
(Unaudited)
| | Three Months Ended | | Six Months Ended | |
| | | | | | | | | |
| | | | | | | | | |
| | July 4, 2015 | | June 28, 2014 | | July 4, 2015 | | June 28, 2014 | |
Net sales | | $1,410 | | $1,448 | | $2,755 | | $2,811 | |
Cost of sales: | | | | | | | | | |
Cost of sales before special charges | | 419 | | 407 | | 812 | | 789 | |
Special charges | | 5 | | 26 | | 7 | | 27 | |
Total cost of sales | | 424 | | 433 | | 819 | | 816 | |
Gross profit | | 986 | | 1,015 | | 1,936 | | 1,995 | |
| | | | | | | | | |
| | | | | | | | | |
Selling, general & administrative expense | | 447 | | 502 | | 877 | | 946 | |
Research & development expense | | 171 | | 178 | | 338 | | 348 | |
Amortization of intangible assets | | 24 | | 21 | | 48 | | 42 | |
Special charges | | 30 | | 25 | | 34 | | 58 | |
Operating profit | | 314 | | 289 | | 639 | | 601 | |
Other expense, net | | 20 | | 21 | | 37 | | 41 | |
Earnings before noncontrolling interest and income taxes | | 294 | | 268 | | 602 | | 560 | |
Income taxes | | 12 | | 22 | | 64 | | 75 | |
Net earnings before noncontrolling interest | | 282 | | 246 | | 538 | | 485 | |
Net loss attributable to noncontrolling interest | | (8) | | (24) | | (14) | | (34) | |
Net earnings attributable to St. Jude Medical, Inc. | | $290 | | $270 | | $552 | | $519 | |
| | | | | | | | | |
| | | | | | | | | |
Diluted net earnings per share attributable to St. Jude Medical, Inc. | | $1.02 | | $0.93 | | $1.93 | | $1.80 | |
Adjusted diluted net earnings per share attributable to St. Jude Medical, Inc. (Non-GAAP) (1) | | $1.03 | | $1.07 | | $1.95 | | $2.07 | |
| | | | | | | | | |
Cash dividends declared per share | | $0.29 | | $0.27 | | $0.58 | | $0.54 | |
| | | | | | | | | |
Weighted average shares outstanding- diluted | | 285.5 | | 288.9 | | 286.3 | | 289.1 | |
(1) See accompanying reconciliation tables.
Non-GAAP Financial Measures Reconciliations (Unaudited)
| | Three Months Ended July 4, 2015 |
| | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | |
(in millions, except per share amounts) | | Earnings before
noncontrolling
interest and
income taxes | | Income taxes | | Effective tax rate | | Net earnings
before
noncontrolling
interest | | Net loss
attributable to
noncontrolling
interest | | Net earnings
attributable to St.
Jude Medical, Inc. | | Diluted net
earnings per share
attributable to St.
Jude Medical, Inc. | | Diluted EPS
growth rate | |
| | | | | | | | | | | | | | | | | |
As reported (GAAP) | | $ | 294 | | $ | 12 | | 4.1% | | $ | 282 | | $ | (8 | ) | $ | 290 | | $ | 1.02 | | 10% | |
| | | | | | | | | | | | | | | | | |
Restructuring activities | | 36 | | 11 | | | | 25 | | - | | 25 | | 0.09 | | | |
Acquisition-related costs | | (10 | ) | 1 | | | | (11 | ) | 4 | | (15 | ) | (0.05) | | | |
Product field action costs and litigation costs | | (1 | ) | - | | | | (1 | ) | - | | (1 | ) | 0.00 | | | |
Amortization of intangible assets | | 24 | | 7 | | | | 17 | | - | | 17 | | 0.06 | | | |
Discrete income tax benefits | | - | | 29 | | | | (29 | ) | - | | (29 | ) | (0.10) | | | |
R&D credit | | - | | (6 | ) | | | 6 | | - | | 6 | | 0.02 | | | |
| | | | | | | | | | | | | | | | | |
As adjusted (Non-GAAP) | | $ | 343 | | $ | 54 | | 15.7% | | $ | 289 | | $ | (4 | ) | $ | 293 | | $ | 1.03 | | -4% | |
| | | | | | | | | | | | | | | | | |
Unfavorable foreign currency impact vs. 2014 | | | | | | | | | | | | | | 0.18 | | | |
| | | | | | | | | | | | | | | | | |
Constant currency as adjusted (non-GAAP) | | | | | | | | | | | | | | $ | 1.21 | | 13% | |
| | Restructuring
activities | | Acquisition-
related costs | | Product field
action costs and
litigation costs | | Total | |
| | | | | | | | | |
Special charges (cost of sales) | | $ | 9 | | $ | - | | $ | (4 | ) | $ | 5 | |
Selling, general & administrative expense | | - | | (11 | ) | - | | (11 | ) |
Research & development expense | | - | | 1 | | - | | 1 | |
Special charges (operating expenses) | | 27 | | - | | 3 | | 30 | |
| | $ | 36 | | $ | (10 | ) | $ | (1 | ) | $ | 25 | |
| | Three Months Ended June 28, 2014 |
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
(in millions, except per share amounts) | | Earnings before
noncontrolling
interest and
income taxes | | Income taxes | | Effective tax rate | | Net earnings
before
noncontrolling
interest | | Net loss
attributable to
noncontrolling
interest | | Net earnings
attributable to St.
Jude Medical, Inc. | | Diluted net
earnings per share
attributable to St.
Jude Medical, Inc. | |
| | | | | | | | | | | | | | | |
As reported (GAAP) | | $ | 268 | | $ | 22 | | 8.2% | | $ | 246 | | $ | (24 | ) | $ | 270 | | $ | 0.93 | |
| | | | | | | | | | | | | | | |
Restructuring activities | | 60 | | 18 | | | | 42 | | - | | 42 | | 0.15 | |
Acquisition-related costs | | 31 | | 6 | | | | 25 | | 16 | | 9 | | 0.03 | |
Product field action costs and litigation costs | | 18 | | 7 | | | | 11 | | - | | 11 | | 0.04 | |
Legal settlements | | (27 | ) | (10 | ) | | | (17 | ) | - | | (17 | ) | (0.06) | |
Amortization of intangible assets | | 21 | | 8 | | | | 13 | | - | | 13 | | 0.04 | |
Discrete income tax benefits | | - | | 24 | | | | (24 | ) | - | | (24 | ) | (0.08) | |
R&D credit | | - | | (4 | ) | | | 4 | | - | | 4 | | 0.01 | |
| | | | | | | | | | | | | | | |
As adjusted (Non-GAAP) | | $ | 371 | | $ | 71 | | 19.1% | | $ | 300 | | $ | (8 | ) | $ | 308 | | $ | 1.07 | |
| | Restructuring
activities | | Acquisition-
related costs | | Product field
action costs and
litigation costs | | Legal settlements | | Total | |
| | | | | | | | | | | |
Special charges (cost of sales) | | $ | 26 | | $ | - | | $ | - | | $ | - | | $ | 26 | |
Selling, general & administrative expense | | - | | 31 | | - | | - | | 31 | |
Special charges (operating expenses) | | 34 | | - | | 18 | | (27) | | 25 | |
| | $ | 60 | | $ | 31 | | $ | 18 | | $ | (27) | | $ | 82 | |
| | Six Months Ended July 4, 2015 |
| | | | | | | | | | | | | | | | | |
| | Earnings before | | | | | | Net earnings | | Net loss | | | | Diluted net | | | |
| | noncontrolling | | | | | | before | | attributable to | | Net earnings | | earnings per share | | | |
| | interest and | | | | | | noncontrolling | | noncontrolling | | attributable to St. | | attributable to St. | | Diluted EPS | |
(in millions, except per share amounts) | | income taxes | | Income taxes | | Effective tax rate | | interest | | interest | | Jude Medical, Inc. | | Jude Medical, Inc. | | growth rate | |
| | | | | | | | | | | | | | | | | |
As reported (GAAP) | | $ | 602 | | $ | 64 | | 10.6% | | $ | 538 | | $ | (14 | ) | $ | 552 | | $ | 1.93 | | 7% | |
| | | | | | | | | | | | | | | | | |
Restructuring activities | | 49 | | 14 | | | | 35 | | - | | 35 | | 0.12 | | | |
Acquisition-related costs | | (32 | ) | 2 | | | | (34 | ) | 4 | | (38 | ) | (0.13 | ) | | |
Product field action costs and litigation costs | | 2 | | 1 | | | | 1 | | - | | 1 | | 0.00 | | | |
Legal settlements | | (10 | ) | (4 | ) | | | (6 | ) | - | | (6 | ) | (0.02 | ) | | |
Amortization of intangible assets | | 48 | | 15 | | | | 33 | | - | | 33 | | 0.12 | | | |
Discrete income tax benefits | | - | | 29 | | | | (29 | ) | - | | (29 | ) | (0.10 | ) | | |
R&D credit | | - | | (11 | ) | | | 11 | | - | | 11 | | 0.04 | | | |
| | | | | | | | | | | | | | | | | |
As adjusted (Non-GAAP) | | $ | 659 | | $ | 110 | | 16.7% | | $ | 549 | | $ | (10 | ) | $ | 559 | | $ | 1.95 | | -6% | |
| | | | | | | | | | | | | | | | | |
Unfavorable foreign currency impact vs. 2014 | | | | | | | | | | | | | | 0.33 | | | |
| | | | | | | | | | | | | | | | | |
Constant currency as adjusted (non-GAAP) | | | | | | | | | | | | | | $ | 2.28 | | 10% | |
| | | | | | Product field | | | | | |
| | Restructuring | | Acquisition- | | action costs and | | | | | |
| | activities | | related costs | | litigation costs | | Legal settlements | | Total | |
| | | | | | | | | | | |
Special charges (cost of sales) | | $ | 13 | | $ | - | | $ | (6) | | $ | - | | $ | 7 | |
Selling, general & administrative expense | | - | | (33 | ) | - | | - | | (33) | |
Research & development expense | | - | | 1 | | - | | - | | 1 | |
Special charges (operating expenses) | | 36 | | - | | 8 | | (10 | ) | 34 | |
| | $ | 49 | | $ | (32 | ) | $ | 2 | | $ | (10 | ) | $ | 9 | |
| | Six Months Ended June 28, 2014 | |
| | | | | | | | | | | | | | | |
| | Earnings before | | | | | | Net earnings | | Net loss | | | | Diluted net | |
| | noncontrolling | | | | | | before | | attributable to | | Net earnings | | earnings per share | |
| | interest and | | | | | | noncontrolling | | noncontrolling | | attributable to St. | | attributable to St. | |
(in millions, except per share amounts) | | income taxes | | Income taxes | | Effective tax rate | | interest | | interest | | Jude Medical, Inc. | | Jude Medical, Inc. | |
| | | | | | | | | | | | | | | |
As reported (GAAP) | | $ | 560 | | $ | 75 | | 13.4% | | $ | 485 | | $ | (34 | ) | $ | 519 | | $ | 1.80 | |
| | | | | | | | | | | | | | | |
Restructuring activities | | 94 | | 29 | | | | 65 | | - | | 65 | | 0.22 | |
Acquisition-related costs | | 33 | | 6 | | | | 27 | | 16 | | 11 | | 0.04 | |
Product field action costs and litigation costs | | 18 | | 7 | | | | 11 | | - | | 11 | | 0.04 | |
Legal settlements | | (27 | ) | (10 | ) | | | (17 | ) | - | | (17 | ) | (0.06 | ) |
Amortization of intangible assets | | 42 | | 16 | | | | 26 | | - | | 26 | | 0.09 | |
Discrete income tax benefits | | - | | 24 | | | | (24 | ) | - | | (24 | ) | (0.08 | ) |
R&D credit | | - | | (8 | ) | | | 8 | | - | | 8 | | 0.03 | |
| | | | | | | | | | | | | | | |
As adjusted (Non-GAAP) | | $ | 720 | | $ | 139 | | 19.3% | | $ | 581 | | $ | (18 | ) | $ | 599 | | $ | 2.07 | |
| | Restructuring
activities | | Acquisition-
related costs | | Product field
action costs and
litigation costs | | Legal settlements | | Total | |
| | | | | | | | | | | |
Special charges (cost of sales) | | $ | 27 | | $ | - | | $ | - | | $ | - | | $ | 27 | |
Selling, general & administrative expense | | - | | 33 | | - | | - | | 33 | |
Special charges (operating expenses) | | 67 | | - | | 18 | | (27 | ) | 58 | |
| | $ | 94 | | $ | 33 | | $ | 18 | | $ | (27 | ) | $ | 118 | |
The sum of the components may not equal the total due to rounding and quantities of shares outstanding in different periods.
Tax rates vary and are applied based on the item’s nature and tax jurisdiction where it is incurred.
2015 Earnings Guidance Reconciliation
(Unaudited)
| | Third Quarter | | Full Year | |
| | | | | |
Estimated 2015 diluted net earnings per share attributable to St. Jude Medical,Inc. | | $0.84 - $0.86 | | $3.70 - $3.74 | |
Estimated restructuring activities | | 0.02 | | 0.16 | |
Estimated acquisition-related costs | | 0.02 | | (0.09) | |
Legal settlements | | - | | (0.02) | |
Estimated amortization of intangible assets | | 0.06 | | 0.23 | |
Discrete income tax benefits | | - | | (0.10) | |
Estimated R&D credit | | 0.02 | | 0.08 | |
Estimated 2015 adjusted diluted net earnings per share attributable to St. Jude Medical, Inc. (Non-GAAP) | | $0.96 - $0.98 | | $3.96 - $4.00 | |
The sum of the components may not equal the total due to rounding and quantities of shares outstanding in different periods.
2015 Sales Guidance Reconciliation
(in millions)
(Unaudited)
| | Third Quarter | | Full Year | |
| | | | | |
2014 total sales | | $1,372 | | $5,622 | |
Estimated 2015 sales | | $1,325 - $1,365 | | $5,435 - $5,575 | |
Estimated 2015 % change vs 2014 | | (3%) - (1%) | | (3%) - (1%) | |
| | | | | |
Estimated unfavorable foreign currency impact vs 2014 | | $105 - $115 | | $385 - $410 | |
Estimated constant currency 2015 total sales (Non-GAAP) | | $1,440 - $1,470 | | $5,845 - $5,960 | |
Estimated 2015 constant currency % change vs 2014 (Non-GAAP) | | 5% - 7% | | 4% - 6% | |
Non-GAAP Financial Measures
The company provides the following non-GAAP financial measures because St. Jude Medical management believes that in order to properly understand the company’s short-term and long-term financial trends, investors may wish to consider the impact of certain adjustments discussed below. St. Jude Medical management uses these non-GAAP financial measures to forecast and evaluate the operational performance of the company as well as to compare results of current periods to prior periods on a consolidated basis.
· Adjusted earnings before noncontrolling interest and income taxes
· Adjusted income taxes and adjusted effective tax rate
· Adjusted net earnings before noncontrolling interest
· Adjusted net loss attributable to noncontrolling interest
· Adjusted net earnings attributable to St. Jude Medical, Inc.
· Adjusted diluted net earnings per share attributable to St. Jude Medical, Inc. and adjusted diluted EPS growth rate
· Adjusted constant currency diluted net earnings per share attributable to St. Jude Medical, Inc. and adjusted constant currency diluted EPS growth rate
The adjustments made to GAAP financial measures result from facts and circumstances that vary in frequency and impact on the Company’s results of operations. The following is an explanation of each of the adjustments that management excludes in calculating its non-GAAP measures.
Restructuring activities – These amounts represent severance costs and other termination benefits, inventory write-offs primarily associated with discontinued product lines, fixed asset write-offs related to assets no longer expected to be utilized and other restructuring costs.
Acquisition-related costs – These amounts consist of contingent consideration fair value adjustments, acquired inventory step-up amortization, other transaction costs and integration costs.
Product field action costs and litigation costs – These amounts primarily relate to inventory write-off and disposal costs, additional warranty and patient monitoring costs, and estimated legal costs for outstanding legal matters associated with product field actions.
Legal settlements – These amounts consist of losses that are probable and reasonably estimable, gains related to favorable resolutions of litigation matters and probable insurance recoveries.
Amortization of intangible assets – These amounts represent the non-cash amortization expenses we recognized for definite-lived intangible assets.
Discrete income tax items – These amounts represent tax effects related to significant unusual or infrequent items not attributable to current-year ordinary income, such as settlement of tax positions and discrete tax adjustments to uncertain tax positions.
R&D credit – These amounts represent the impact of the federal research and development tax credit to present comparative periods assuming that the tax credit had been enacted in all periods presented.
Foreign currency impact – These amounts represent the impact to net sales and adjusted diluted net earnings per share attributable to St. Jude Medical, Inc. after translating net sales and the consolidated statement of earnings at comparable prior period foreign currency exchange rates.
The company also provides constant currency sales growth and constant currency adjusted EPS growth because St. Jude Medical management believes that in order to properly understand the Company’s short-term and long-term financial trends, investors may wish to consider the impact of foreign currency translation on net sales and adjusted EPS. St. Jude Medical management uses constant currency sales growth and constant currency adjusted EPS growth to forecast and evaluate the operational performance of the company as well as to compare sales and adjusted EPS of current periods to prior periods.
Non-GAAP financial measures used by the company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider non-GAAP measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.
